Aardvark Therapeutics, Inc. Common Stock (AARD) financial statements and ratios from SEC XBRL: revenue $0.00 (TTM), revenue growth -53.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $0.00 |
| Revenue Growth (YoY) | -53.3% |
| EPS Growth (YoY) | 0.0% |
| FCF Growth (YoY) | -17.5% |
| Price / Book | 1.99 |
| Price / Sales | 42.04 |
| FCF Yield | -51.4% |
| Altman Z-Score | 6.34 (safe) |
| Sector P/E (Healthcare) | 21.7 |
AARD overview · AARD earnings · AARD KPIs · AARD investor relations · AARD ownership · AARD peers · AARD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.